

City of Flint, Michigan

*Third Floor, City Hall
1101 S. Saginaw Street
Flint, Michigan 48502
www.cityofflint.com*



Meeting Agenda – FINAL

Wednesday, JULY 5, 2023

5:00 PM

GENESEE COUNTY ADMINISTRATION BUILDING

GOVERNMENTAL OPERATIONS COMMITTEE

Dennis Pfeiffer, Chairperson, Ward 8

Eric Mays, Ward 1

Quincy Murphy, Ward 3

Jerri Winfrey-Carter, Ward 5

Allie Herkenroder, Ward 7

Ladel Lewis, Ward 2

Judy Priestley, Ward 4

Tonya Burns, Ward 6

Eva L. Worthing, Ward 9

Davina Dunshua, City Clerk

ROLL CALL

REQUEST FOR CHANGES AND/OR ADDITIONS TO THE AGENDA

PUBLIC SPEAKING

Members of the public shall have no more than two (2) minutes to address the City Council on any subject. Only one speaking opportunity per speaker.

COUNCIL RESPONSE

Councilpersons may respond to any public speaker, but only one response and only when all public speakers have been heard. Individual council response is limited to two (2) minutes and is subject to all rules of decorum and discipline.

CONSENT AGENDA

Per the amended Rules Governing Meetings of the Flint City Council (as adopted by the City Council on Monday, February 27, 2023), the Presiding Officer or Chair may request the adoption of a "Consent Agenda". After a motion to adopt a Consent Agenda is made and seconded, the Presiding Officer or Chair shall ask for separations. Any agenda item on a Consent Agenda shall be separated at the request of any Councilmember. After any separations, there is no debate on approving the Consent Agenda - it shall be voted on or adopted without objection.

RESOLUTIONS

230162 Administration Process/American Rescue Plan Act (ARPA) Funds

Resolution resolving that the Flint City Council authorizes and approves (1) The individual ARPA grants requests which were already submitted prior to the March 27, 2023 cut-off date are hereby deemed valid; and furthermore,(2) The application period for ARPA grant funding for individual homeowners is hereby reopened for three weeks or twenty-one (21) days from the date of the passage of this Resolution; and furthermore, (3) Each individual homeowner grant request, both those previously submitted and those to-be submitted, shall be processed by the City, or by the City's representative authorized to administrator ARPA funds, within 180 days from their receipt of the said request; however, requests submitted prior to the March 27, 2023 cut-off date shall be given priority over new requests; and furthermore, (4) Within sixty (60) days from the passage of this Resolution, the City's Legal Department is directed to issue a Request for Proposal (RFP) and accept bids from a third-party claims administrator who will be responsible for administering the ARPA funds; and furthermore,(5) Within thirty (30) days after the RFP period closes, those bid requests are to be presented to the Flint City Council for awarding of the contract; and furthermore, (6) The Initial Request Form which was previously used to submit grant requests will continue to be used for new grant requests until the third-party claims administrator is selected and provides a request form or application of their own

230203 Resignation/Councilmember Allie Herkenroder

Resolution resolving that the Flint City Council accepts the resignation of Councilmember Allie Herkenroder (effective July 1, 2023).

APPOINTMENTS

230118 Appointment/Hurley Board of Hospital Managers/Dr. Khalid M. Ahmed

Resolution resolving that the Flint City Council approves the appointment of Dr. Khalid M. Ahmed (2700 Robert T. Longway, Suite B, Flint, Michigan, 48503) to the Hurley Board of Hospital Managers for a five-year term, with such term commencing April 30, 2023, and expiring April 30, 2028. [NOTE: Mayor Sheldon A. Neeley recommends the appointment of Dr. Ahmed to replace Frances Gilcreast, whose term on the Board expires April 30, 2023.

230177 Reappointment/Hurley Board of Hospital Managers/Charlotte Edwards

Resolution resolving that the Flint City Council approves the reappointment of Charlotte Edwards (, Flint, Michigan,) to the Hurley Board of Hospital Managers for a five-year term, with such term commencing immediately and expiring April 30, 2028.

ADJOURNMENT

230162

RESOLUTION:

PRESENTED: 5-29-2023

ADOPTED: _____

**RESOLUTION RELATIVE TO AMERICAN RESCUE PLAN ACT (ARPA) FUNDS
ADMINISTRATION PROCESS TO THE INDIVIDUALS OF FLINT**

BY THE CITY COUNCIL:

The Flint City Council acknowledges the existence of approximately \$30-40 million of American Rescue Plan Act (ARPA) funds left to be allocated within the City of Flint.

This resolution allocates \$15,000,000 (Fifteen-Million Dollars) of the ARPA funds as a community grant program to be administered directly to individual homeowners who apply, and are approved therefor.

Further, the Flint City Council acknowledges the existence of approximately 800 (Eight-Hundred) individual grant requests, claims, and/or applications which were submitted prior to the March 27, 2023 cut-off date. It is the position of the Flint City Council that this cut-off date was premature given the significant and ongoing community need.

WHEREFORE, be it here resolved that:

- (1) The individual grants requests which were already submitted prior to the March 27, 2023 cut-off date are hereby deemed valid; and furthermore,
- (2) The application period for ARPA grant funding for individual homeowners is hereby reopened for three weeks or twenty-one (21) days from the date of the passage of this Resolution; and furthermore,
- (3) Each individual homeowner grant request, both those previously submitted and those to-be submitted, shall be processed by the City, or by the City's representative authorized to administrator ARPA funds, within 180 days from their receipt of the said request; however, requests submitted prior to the March 27, 2023 cut-off date shall be given priority over new requests; and furthermore,
- (4) Within sixty (60) days from the passage of this Resolution, the City's Legal Department is directed to issue a Request for Proposal (RFP) and accept bids from a third-party claims administrator who will be responsible for administering the ARPA funds; and furthermore,
- (5) Within thirty (30) days after the RFP period closes, those bid requests are to be presented to the Flint City Council for awarding of the contract, and furthermore.

- (6) The Initial Request Form which was previously used to submit grant requests will continue to be used for new grant requests until the third-party claims administrator is selected and provides a request form or application of their own.

IT IS RESOLVED, that the Flint City Council authorizes and approves the foregoing.

APPROVED BY CITY COUNCIL:

Allie Herkenroder, City Council President

APPROVED AS TO FORM:

William Kim, City Attorney

230203



RESOLUTION NO.: _____

PRESENTED: JUL - 5 2023

ADOPTED: _____


Resolution Accepting the Resignation of Councilmember Allie Herkenroder

Allie Herkenroder, Councilmember for the 7th Ward, tendered her resignation from the Flint City Council effective July 1, 2023.

BE IT RESOLVED that the Flint City Council accepts the resignation of Councilmember Allie Herkenroder.

FOR THE CITY COUNCIL

APPROVED AS TO FORM:


William Kim (Jun 29, 2023 17:55 EDT)

William Y. Kim, City Attorney

230118



RESOLUTION NO.: _____
PRESENTED: APR 19 2023
ADOPTED: _____

**RESOLUTION RECOMMENDING THE RE-APPOINTMENT OF DR. KHALID M. AHMED
TO THE HURLEY BOARD OF HOSPITAL MANAGERS.**

BY THE MAYOR:

Mayor Sheldon A. Neeley recommends the appointment of Dr. Khalid M. Ahmed to fill the expired term of Frances Gilcrest that expires on April 30, 2023; and


Mayor Sheldon A. Neeley recommends the appointment of Dr. Khalid M. Ahmed (2700 Robert T- Longway. Suite B, Flint, MI 48503) to complete a five-year term on the Hurley Board of Hospital Managers, with such term that commenced on April 30, 2023, and expires April 30, 2028.

THEREFORE, BE IT RESOLVED that the Flint City Council approves the appointment of Dr. Khalid M. Ahmed (2700 Robert T-Longway. Suite B, Flint, MI 48503) to serve a five-year term on the Hurley Board of Hospital Managers, with such term commenced on April 30, 2023, and expires April 30, 2028.

APPROVED AS TO FORM:


William Kim, Chief Legal Officer

FOR THE CITY OF FLINT:


Sheldon A. Neeley, Mayor

FOR THE CITY COUNCIL:

.....

KHALID M. AHMED, M.D

2700 Robert T-longway Blvd. Suite B, Flint, MI 48503 ♦ P. 810-235-2004 ♦ F.810-235-2841 ♦ kahmed2700@gmail.com

EDUCATION

- 2006** American Board of Internal Medicine
- 1992** Royal College of Physicians of Ireland
- 1981** M.B.B.S., Faculty of Medicine University of Khartoum,
Khartoum, Sudan

CURRENT POSITIONS

- 2021 - Present** Chief of Staff, Hurley Medical Center, Flint, MI
- 2021 - 2022** President, Genesee County Medical Society
- 2018 - Present** Board member, Genesee County Medical Society
- 2018 - Present** Board member, Islamic Medical Association of Mid-Michigan
- 2012 - 2016** Board member, Genesee Academy School
- 2014 - Present** Clinical Director, Internal Medicine, Hurley Medical Center. Flint, MI
- 2013 - 2021** Chairman, Department of Medicine, Hurley Medical Center, Flint, MI.
- 2010 - 2019** Vice Chief of Staff, Interim Chief of staff, Hurley Medical Center, Flint, MI
- 1996 - Present** Attending & Consultant Physician, Department of Internal Medicine. Hurley Medical Center and Michigan Health Specialists, Flint, MI
- 1996 - Present** Associate Professor of Internal Medicine, Michigan State University, College of Human Medicine, Flint, MI.
- 1996 - Present** Internal Medicine Physician, Flint, MI

AWARDS

Finnacis Award, Hurley Medical Center, 2013

Physician of the Year, Arab American Heritage Council, 2019

ORGANIZATION

Active Member of the African American Physicians Association.

Active Member of the Genesee County Medical Society.

Active Member of the Michigan State Medical Society.

Active Member of the American Medical Association.

Active Member of the American College of Physicians

AFFILIATION WITH RESEARCH CENTER

2015-Present Principal investigator, Flint Clinical Research PLLC, Flint, MI


2015-Present Sub-investigator, Elite Research Center, Flint, MI

CLINICAL RESEARCH EXPERIENCE AND PUBLICATIONS

- A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects with Moderately to Severely Active Crohn's Disease(CULTIVATE). **2020**
- A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of Olorinab in Subjects with Irritable Bowel Syndrome Experiencing Abdominal Pain (CAPTIVATE). **2019**
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis (ELEVATE). **2019**
- A randomized, double blind controlled factorial clinical trial of edetate disodium-based chelation and high dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infarction. **2018**
- A randomized, Parallel –group , Placebo-Controlled, clinical endpoint bioequivalence study of generic Fluticasone Propionate 100 ug and Salmeterol Xinafoate 50 ug inhalation powder compared with Advair DiskusR 100/50 in subjects with Asthma. **2018**
- A randomized, double blind controlled factorial clinical trial of Edetate disodium-based chelation and high-dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infarction. **2018**
- A Phase IV, 12-week, randomized, double-blind, triple dummy study to compare single inhaler triple therapy, Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMBC/VT) with multiple inhaler therapy (Budesonide/Formoterol plus Tiotropium) based on lung function and symptoms in participants with chronic obstructive pulmonary disease. **2018**

- A Phase 3, multi-center, multi-national, placebo controlled, randomized, double-blind 26-week study to assess the safety and efficacy of CaPre® in patients with severe hypertriglyceridemia. **2018**
- Inflammatory Bowel Disease registry. Corrona. **2017**
- A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients with post-herpetic neuralgia (EMPHENE). **2017**
- A randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome. **2017**
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 12 Weeks Followed by a 4-Week Off-Drug Phase in Patients with Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease, VK2809-201. **2017**
- A double-blind, randomized, placebo-controlled, parallel-group, phase IV study to evaluate to effect of Aclidinium Bromide on long-term cardiovascular safety and COPD exacerbations in patients with moderate to very severe COPD (ASCENT COPD). **2016**
- A Multi-Center, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin 5 mg Co – administered with Dapagliflozin 5 mg compared to Saxagliptin 5 mg or Dapagliflozin 5 mg all given as add –on therapy to metformin in Patients with Type 2 Diabetes who have inadequate Glycemic Control on Metformin Alone. **2016**
- A phase 2 Randomized, Double Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Gemcabene in Patients with Severe Hypertriglyceridemia (INDIGO-1). **2016**
- A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of Roxadustat (FG-4592) for the treatment of anemia in chronic kidney disease patients not on dialysis. **2015**
- An open label, long-term study to assess the immunogenicity of Linaclotide administered orally to adult patients with irritable bowel syndrome with constipation or chronic idiopathic constipation. **2015**
- Ahmed K., Managing Malnutrition in Inflammatory Bowel Disease, Hospital Physicians. Vol 30 12:13-17 1994
- Ahmed K., Saeed E. Nephrotic Syndrome and Pulmonary Artery Thrombosis, case report, American Journal of Nephrology. 1995; 15:181-185
- Ahmed K., Jackson L. Heparin Use In Right Arterial Thrombosis, Oral Presentation ACP Michigan Chapter Annual Meeting, Traverse City 1995
- Ahmed K. , Chan S. Mixed Lineage Hematologic Malignancy (Myeloblastic and T Lymphoblastic), Abstract, Blood Vol 86 No. 10 Supp. Nov. 1995
- Ahmed K. , Isawi I. Use of Flecainide for Refractory Arterial Tachycardia of Pregnancy, A case report, Manuscript Accepted for Publication, American Journal of Critical Care.
- Ahmed K., Filas O., Rapid Infusion of Magnesium Sulfate in Severe Acute Asthma, Case Series, Oral Presentation, ACP Michigan Chapter Conference, Sept. 1995
- Ahmed K., Seedahmed E. Holt-Oram Syndrome. Cases Presentations Community Wide Research Forum, April 2005. Flint, Michigan.

230177



RESOLUTION NO.: _____

PRESENTED: JUN - 7 2023

ADOPTED: _____


**RESOLUTION APPROVING RE-APPOINTMENT OF CHARLOTTE EDWARDS
TO THE HURLEY BOARD OF HOSPITAL MANAGERS.**

Section 6-201(A) of the Flint City Charter provides that members of the Board of Hospital Managers shall “consist of fifteen (15) members appointed by the Mayor with the approval of the City Council.”

Pursuant to that authority, Mayor Sheldon A. Neeley re-appoints Charlotte Edwards, to the Board of Hospital Managers, whose term expires April 30, 2022.

BE IT RESOLVED that the Flint City Council approves the re-appointment of Charlotte Edwards to serve a five-year term on the Hurley Board of Hospital Managers, with such term commencing immediately and expiring on April 30, 2028.

FOR THE CITY OF FLINT:



Sheldon A. Neeley, Mayor

APPROVED BY CITY COUNCIL:

APPROVED AS TO FORM:

William Kim, City Attorney